Markers for Chronic Obstructive Pulmonary Disease (COPD)

Withdrawn

• Conditions: Healthy Non-smokers; Current Smokers; COPD Patients

• Registration Number: NCT00180622
• Lead Sponsor: Imperial College London

Brief Summary

The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).

Detailed Description

Not available

Study Timeline

• Study Start: 2001-07-01
• Primary Completion: 2002-07-01
• Study Completion: 2002-07-01
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-16
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-02
• Last Update Posted: 2019-07-05

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Healthy non-smokers

• FEV1 >80% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists

Current smokers

• FEV1 no less than 80% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists
• Smoking history of > 10 pack-years

Moderate COPD

• FEV1 40-59% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists
• Smoking history of > 10 pack-years**

Severe COPD

• FEV1 <40% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists
• Smoking history of > 10 pack-years

Exclusion Criteria

• FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists
• Asthma
• unstable disease (FEV1 <35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital; 🇬🇧 London, United Kingdom